Marta Elosua‐González
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marta Elosua‐González has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Fátima Tous‐Romero
Department of Dermatology Hospital Universitario 12 de Octubre Madrid Spain
4 shared publications - Ángel Manuel Rosell-Díaz
Department of Dermatology Hospital Universitario Puerta de Hierro Majadahonda Madrid Spain
4 shared publications - David Pesqué
Department of Dermatology Hospital del Mar Research Institute Barcelona Spain
3 shared publications - Elena García-Zamora
Dermatology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain
3 shared publications - Gaston Roustan-Gullón
Department of Dermatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
3 shared publications - Jose Luis Lopez Estebaranz
Department of Dermatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
3 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (11) , 1473
Longitudinal Effectiveness and Laboratory Safety Profile of Janus Kinase Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Real-World Study
Background/Objectives: Janus kinase inhibitors (JAKis) are effective treatments for moderate-to-severe atopic dermatitis (AD), although longitudinal real-world data on their laboratory safety profile remain limited and there is scarce information regarding whether laboratory changes differ according to JAKi use. So, the main objective of this study was to evaluate longitudinal laboratory changes in patients with AD treated with JAKis in routine clinical practice and to evaluate these changes across different types of JAKis. Methods: We conducted a retrospective observational study including patients with moderate-to-severe AD who initiated treatment with abrocitinib, upadacitinib, or baricitinib. Demographic, clinical, laboratory, and patient-reported outcome data were collected at baseline and after 4, 12–16, 24–32, and 48–52 weeks. Longitudinal changes were analyzed using REML mixed-effects models with categorical visit and a patient-specific random intercept, using logarithmic transformations for skewed laboratory parameters. Results: Forty-three patients were included. EASI decreased from 21.18 ± 8.82 at baseline to 6.06 ± 8.27 at week 4 and 7.85 ± 8.63 at weeks 48–52, while pruritus NRS decreased from 7.15 ± 2.48 to 2.23 ± 2.78 and 4.34 ± 3.28, respectively (p < 0.001). At weeks 24–32, total cholesterol (+29.26), LDL cholesterol (+16.09), HDL cholesterol (+6.57), and MCV (+2.12) increased significantly, whereas CRP (−2.87), leukocyte (−1.07), and neutrophil counts (−1.07) decreased significantly. Mean creatinine changes were small. No significant longitudinal changes were observed in AST, ALT, triglycerides or hemoglobin. Few between-treatment differences were identified. No MACE, VTE or changes in lipid-lowering treatment were documented during recorded follow-up. Conclusions: JAKis provided substantial clinical benefit with a favorable longitudinal laboratory safety profile. Laboratory abnormalities were generally mild and consistent with the known safety profile of this class.
- 13 November 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (11) , 1473
Open AccessLongitudinal Effectiveness and Laboratory Safety Profile of Janus Kinase Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Real-World Study
Background/Objectives: Janus kinase inhibitors (JAKis) are effective treatments for moderate-to-severe atopic dermatitis (AD), although longitudinal real-world data on their laboratory safety profile remain limited and there is scarce information regarding whether laboratory changes differ according to JAKi use. So, the main objective of this study was to evaluate longitudinal laboratory changes in patients with AD treated with JAKis in routine clinical practice and to evaluate these changes across different types of JAKis. Methods: We conducted a retrospective observational study including patients with moderate-to-severe AD who initiated treatment with abrocitinib, upadacitinib, or baricitinib. Demographic, clinical, laboratory, and patient-reported outcome data were collected at baseline and after 4, 12–16, 24–32, and 48–52 weeks. Longitudinal changes were analyzed using REML mixed-effects models with categorical visit and a patient-specific random intercept, using logarithmic transformations for skewed laboratory parameters. Results: Forty-three patients were included. EASI decreased from 21.18 ± 8.82 at baseline to 6.06 ± 8.27 at week 4 and 7.85 ± 8.63 at weeks 48–52, while pruritus NRS decreased from 7.15 ± 2.48 to 2.23 ± 2.78 and 4.34 ± 3.28, respectively (p < 0.001). At weeks 24–32, total cholesterol (+29.26), LDL cholesterol (+16.09), HDL cholesterol (+6.57), and MCV (+2.12) increased significantly, whereas CRP (−2.87), leukocyte (−1.07), and neutrophil counts (−1.07) decreased significantly. Mean creatinine changes were small. No significant longitudinal changes were observed in AST, ALT, triglycerides or hemoglobin. Few between-treatment differences were identified. No MACE, VTE or changes in lipid-lowering treatment were documented during recorded follow-up. Conclusions: JAKis provided substantial clinical benefit with a favorable longitudinal laboratory safety profile. Laboratory abnormalities were generally mild and consistent with the known safety profile of this class.
- Open Access
- 6 July 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Dupilumab in Difficult-to-treat Chronic Spontaneous Urticaria: A Real-world Multicentre Cohort Study
Chronic spontaneous urticaria (CSU) remains difficult to manage in patients refractory to antihistamines and omalizumab. Although dupilumab has recently been approved and incorporated into international guidelines, real-world evidence remains limited, particularly in treatment-refractory populations. We conducted a multicentre ambispective cohort study across 16 Spanish hospitals including adults with CSU, with or without concomitant chronic inducible urticaria, treated with dupilumab and followed for ≥4 weeks. The primary outcome was well-controlled disease within 24 weeks (Urticaria Control Test ≥12 and Urticaria Activity Score over 7 days≤6). Fiftyone patients were included; 92.0% had previously received omalizumab. At week 24, 69.7% (23/33) achieved well-controlled disease and 39.4% (13/33) complete control. Among patients with available week-52 data, 90.5% (19/21) and 61.9% (13/21), respectively, achieved these outcomes. Concomitant therapy use declined from 94.1% at baseline to 55.6% at week 52. Among omalizumab-experienced patients evaluable at week 24, dupilumab response was lower in prior nonresponders than in those with at least partial response to omalizumab (40% vs 85%, p=0.011). Atopic comorbidities were associated with greater UAS7 reduction (p=0.018). Dupilumab was well tolerated, with mostly mild adverse events. In routine clinical practice, dupilumab provides effective disease control in patients with difficult-totreat CSU, including most omalizumab-experienced individuals.
- 6 July 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessDupilumab in Difficult-to-treat Chronic Spontaneous Urticaria: A Real-world Multicentre Cohort Study
Chronic spontaneous urticaria (CSU) remains difficult to manage in patients refractory to antihistamines and omalizumab. Although dupilumab has recently been approved and incorporated into international guidelines, real-world evidence remains limited, particularly in treatment-refractory populations. We conducted a multicentre ambispective cohort study across 16 Spanish hospitals including adults with CSU, with or without concomitant chronic inducible urticaria, treated with dupilumab and followed for ≥4 weeks. The primary outcome was well-controlled disease within 24 weeks (Urticaria Control Test ≥12 and Urticaria Activity Score over 7 days≤6). Fiftyone patients were included; 92.0% had previously received omalizumab. At week 24, 69.7% (23/33) achieved well-controlled disease and 39.4% (13/33) complete control. Among patients with available week-52 data, 90.5% (19/21) and 61.9% (13/21), respectively, achieved these outcomes. Concomitant therapy use declined from 94.1% at baseline to 55.6% at week 52. Among omalizumab-experienced patients evaluable at week 24, dupilumab response was lower in prior nonresponders than in those with at least partial response to omalizumab (40% vs 85%, p=0.011). Atopic comorbidities were associated with greater UAS7 reduction (p=0.018). Dupilumab was well tolerated, with mostly mild adverse events. In routine clinical practice, dupilumab provides effective disease control in patients with difficult-totreat CSU, including most omalizumab-experienced individuals.
- 21 April 2026
- Published by Wiley in Contact Dermatitis
Allergic Contact Dermatitis to Bakuchiol Used for Photodamage Prevention: A Case Report
- 21 April 2026
- Published by Wiley in Contact Dermatitis
Allergic Contact Dermatitis to Bakuchiol Used for Photodamage Prevention: A Case Report
- Open Access
- 19 February 2026
- Published by Wiley in Contact Dermatitis
- Vol. 94 (6) , 614-623
Clinical Factors Associated With Current Relevance in Allergic Contact Dermatitis: Development of Predictive Models Based on Data From the Spanish Contact Dermatitis Register ( REIDAC )
Background: Current relevance of positive patch‐test reactions guides management in allergic contact dermatitis (ACD), yet its clinical predictors and the use of predictive models in clinical practice remain underused. Objectives: To identify demographic and clinical factors associated with current relevance in ACD and to develop overall and allergen‐specific predictive models. Methods: A multicentric REIDAC study included data from patch‐tested patients with the Spanish baseline series. Exposure history, anatomical sites, atopic status, and occupational data were recorded. Logistic regression (LR) models were trained and internally validated to predict current relevance overall and for top frequent allergens. Model discrimination was assessed with area under the receiver‐operating characteristic curve (AUC). Results: Among 17 005 patients, 4077 (24.0%) had at least one currently relevant reaction. The final overall LR model achieved an AUC for the validation sample of 0.679. Allergen‐specific AUC parameters (LR) varied among allergens but performed best for nickel (AUC = 0.770). The independent factors associated with current relevance were female gender, specific body sites (hand, neck, head, leg, feet) and two occupations (hairdresser and construction workers). The use of other models (LASSO, gradient boosting) revealed similar results. Conclusions: Prediction modelling may moderately predict current relevance in ACD and several clinical variables are associated with current relevance in ACD.
- 19 February 2026
- Published by Wiley in Contact Dermatitis
- Vol. 94 (6) , 614-623
Open AccessClinical Factors Associated With Current Relevance in Allergic Contact Dermatitis: Development of Predictive Models Based on Data From the Spanish Contact Dermatitis Register ( REIDAC )
Background: Current relevance of positive patch‐test reactions guides management in allergic contact dermatitis (ACD), yet its clinical predictors and the use of predictive models in clinical practice remain underused. Objectives: To identify demographic and clinical factors associated with current relevance in ACD and to develop overall and allergen‐specific predictive models. Methods: A multicentric REIDAC study included data from patch‐tested patients with the Spanish baseline series. Exposure history, anatomical sites, atopic status, and occupational data were recorded. Logistic regression (LR) models were trained and internally validated to predict current relevance overall and for top frequent allergens. Model discrimination was assessed with area under the receiver‐operating characteristic curve (AUC). Results: Among 17 005 patients, 4077 (24.0%) had at least one currently relevant reaction. The final overall LR model achieved an AUC for the validation sample of 0.679. Allergen‐specific AUC parameters (LR) varied among allergens but performed best for nickel (AUC = 0.770). The independent factors associated with current relevance were female gender, specific body sites (hand, neck, head, leg, feet) and two occupations (hairdresser and construction workers). The use of other models (LASSO, gradient boosting) revealed similar results. Conclusions: Prediction modelling may moderately predict current relevance in ACD and several clinical variables are associated with current relevance in ACD.
- 20 August 2024
- Published by Wiley in Contact Dermatitis
- Vol. 91 (5) , 379-386
An emerging epidemic of allergic contact dermatitis due to phytonadione epoxide (oxidised vitamin K1)
Background: Reports of allergic contact dermatitis (ACD) to phytonadione epoxide (PE) in cosmetics suggest that PE is as powerful a sensitiser as its parent compound phytonadione.Objective: To evaluate a case series of ACD to PE in Spain.Methods: We reviewed the records of 20 patients with ACD to cosmetics containing PE diagnosed across Spain between January 2019 and June 2023.Results: All 20 patients developed patch test (PT) or repeated open application test (ROAT) reactions to cosmetics containing PE. All involved women with eyelid eczema. PT or ROAT with PE preparations were positive in 17/20 (85%). PE at 1%, 5%, 10% and 20% in pet. was patch‐tested in 8/17, 14/17, 11/17 and 8/17 patients; being positive in 6/8 (75%), 13/14 (92.85%), 11/11 (100%) and 8/8 (100%), respectively.Conclusion: Regulators should, not only ban the specific dangerous cosmetic ingredients, but also consider to ban or keep under close surveillance those closely related products or derivatives that might potentially cause similar harmful effects. PTs with PE are suggested to be performed at a 5% concentration in pet. Higher concentrations (10% pet.) should be tested whenever PTs with 5% pet. PE are negative.
- 20 August 2024
- Published by Wiley in Contact Dermatitis
- Vol. 91 (5) , 379-386
An emerging epidemic of allergic contact dermatitis due to phytonadione epoxide (oxidised vitamin K1)
Background: Reports of allergic contact dermatitis (ACD) to phytonadione epoxide (PE) in cosmetics suggest that PE is as powerful a sensitiser as its parent compound phytonadione.Objective: To evaluate a case series of ACD to PE in Spain.Methods: We reviewed the records of 20 patients with ACD to cosmetics containing PE diagnosed across Spain between January 2019 and June 2023.Results: All 20 patients developed patch test (PT) or repeated open application test (ROAT) reactions to cosmetics containing PE. All involved women with eyelid eczema. PT or ROAT with PE preparations were positive in 17/20 (85%). PE at 1%, 5%, 10% and 20% in pet. was patch‐tested in 8/17, 14/17, 11/17 and 8/17 patients; being positive in 6/8 (75%), 13/14 (92.85%), 11/11 (100%) and 8/8 (100%), respectively.Conclusion: Regulators should, not only ban the specific dangerous cosmetic ingredients, but also consider to ban or keep under close surveillance those closely related products or derivatives that might potentially cause similar harmful effects. PTs with PE are suggested to be performed at a 5% concentration in pet. Higher concentrations (10% pet.) should be tested whenever PTs with 5% pet. PE are negative.
- 26 January 2023
- Published by Springer Nature in Journal of Ultrasound
- Vol. 26 (1) , 307-311
Sonography of monkeypox cutaneous lesions
The present global outbreak of monkeypox has reached more than 79,000 cases by November 2022. While clinical features have been extensively studied, ultrasound findings in monkeypox skin lesions have not been described to date. In our work, we performed a complete sonographic study with Doppler and elastography of 3 patients with polymerase chain reaction-proven monkeypox. The most characteristic findings in skin lesions were hyperechoic epidermal thickening, dermo-hypodermal thickening with focal hypoechogenicity and increased intralesional vascularization. Regarding lymphadenopathies, we found vascularization of hilar distribution and an increased cortical stiffness and shoft hiliar area.
- 26 January 2023
- Published by Springer Nature in Journal of Ultrasound
- Vol. 26 (1) , 307-311
Sonography of monkeypox cutaneous lesions
The present global outbreak of monkeypox has reached more than 79,000 cases by November 2022. While clinical features have been extensively studied, ultrasound findings in monkeypox skin lesions have not been described to date. In our work, we performed a complete sonographic study with Doppler and elastography of 3 patients with polymerase chain reaction-proven monkeypox. The most characteristic findings in skin lesions were hyperechoic epidermal thickening, dermo-hypodermal thickening with focal hypoechogenicity and increased intralesional vascularization. Regarding lymphadenopathies, we found vascularization of hilar distribution and an increased cortical stiffness and shoft hiliar area.
- 21 October 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (4) , E560-E561
Dermatoscopic features in monkeypox
- 21 October 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (4) , E560-E561
Dermatoscopic features in monkeypox
- Open Access
- 1 May 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 97 (3) , 358-361
Remissão clínica de infecção disseminada por molusco contagioso em paciente com dermatite atópica tratada com dupilumabe
- 1 May 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 97 (3) , 358-361
Open AccessRemissão clínica de infecção disseminada por molusco contagioso em paciente com dermatite atópica tratada com dupilumabe
- Open Access
- 17 March 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 97 (3) , 358-361
Clinical remission of disseminated molluscum contagiosum infection in a patient with atopic dermatitis treated with dupilumab
- 17 March 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 97 (3) , 358-361
Open AccessClinical remission of disseminated molluscum contagiosum infection in a patient with atopic dermatitis treated with dupilumab